$ICCC
IMMUCELL CORP /DE/ Stock $iccc

$iccc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023024080 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$3.447M	$3.911M	$18.57M
YoY Change	-42.55%	-28.16%	-3.51%
Cost Of Revenue	$3.146M	$2.919M	$10.92M
YoY Change	8.61%	1.24%	3.14%
Gross Profit	$300.8K	$992.0K	$7.649M
YoY Change	-90.31%	-61.26%	-11.63%
Gross Profit Margin	8.73%	25.36%	41.19%
Selling, General & Admin	$1.446M	$1.576M	$5.454M
YoY Change	13.51%	18.9%	28.94%
% of Gross Profit	480.91%	158.87%	71.3%
Research & Development	$1.110M	$1.050M	$4.494M
YoY Change	7.18%	-3.66%	7.81%
% of Gross Profit	369.17%	105.85%	58.75%
Depreciation & Amortization	$652.1K	$604.3K	$2.468M
YoY Change	4.91%	0.51%	0.3%
% of Gross Profit	216.82%	60.91%	32.27%
Operating Expenses	$2.557M	$2.626M	$9.948M
YoY Change	10.67%	8.72%	18.45%
Operating Profit	-$2.256M	-$1.634M	-$2.299M
YoY Change	-384.5%	-1223.72%	-993.21%
Interest Expense	$89.98K	-$28.93K	$348.5K
YoY Change	-232.29%	-59.52%	-217.93%
% of Operating Profit
Other Income/Expense, Net	-$57.49K	-$32.00K	-$187.0K
YoY Change	-6863.41%
Pretax Income	-$2.314M	-$1.666M	-$2.486M
YoY Change	-413.99%	-2313.66%	3496.12%
Income Tax	$1.525K	$2.000K	$8.000K
% Of Pretax Income
Net Earnings	-$2.315M	-$1.668M	-$2.494M
YoY Change	-414.69%	-2350.1%	3085.59%
Net Earnings / Revenue	-67.17%	-42.65%	-13.43%
Basic Earnings Per Share	-$0.30		-$0.32
Diluted Earnings Per Share	-$0.30	-$0.22	-$0.32
COMMON SHARES
Basic Shares Outstanding	7.747M shares	7.747M shares	7.745M shares
Diluted Shares Outstanding	7.747M shares		7.745M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.096M	$5.792M	$5.792M
YoY Change	-73.8%	-43.14%	-43.14%
Cash & Equivalents	$3.096M	$5.792M	$5.792M
Short-Term Investments
Other Short-Term Assets	$681.8K	$363.9K	$363.9K
YoY Change	76.01%	35.42%	35.42%
Inventory	$6.328M	$6.039M	$6.039M
Prepaid Expenses		$363.9K
Receivables	$2.090M	$1.759M	$1.759M
Other Receivables	$51.79K	$42.18K	$42.18K
Total Short-Term Assets	$12.25M	$13.99M	$13.99M
YoY Change	-33.07%	-13.96%	-13.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.46M	$28.44M	$30.64M
YoY Change	0.89%	5.76%	9.41%
Goodwill	$95.56K	$95.56K
YoY Change		0.0%
Intangibles	$52.54K	$57.31K
YoY Change		-25.0%
Long-Term Investments
YoY Change
Other Assets	$87.78K	$76.63K	$76.63K
YoY Change	281.66%	193.43%	193.38%
Total Long-Term Assets	$30.87M	$30.87M	$30.87M
YoY Change	8.71%	9.45%	9.45%
TOTAL ASSETS
Total Short-Term Assets	$12.25M	$13.99M	$13.99M
Total Long-Term Assets	$30.87M	$30.87M	$30.87M
Total Assets	$43.12M	$44.86M	$44.86M
YoY Change	-7.66%	0.89%	0.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$794.9K	$790.0K	$790.0K
YoY Change	20.06%	6.03%	6.03%
Accrued Expenses	$840.8K	$1.094M	$1.094M
YoY Change	71.1%	40.96%	40.96%
Deferred Revenue
YoY Change
Short-Term Debt	$1.000M	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.064M	$1.039M	$1.039M
YoY Change	12.35%	27.98%	27.98%
Total Short-Term Liabilities	$3.838M	$3.072M	$3.072M
YoY Change	63.24%	21.21%	21.21%
LONG-TERM LIABILITIES
Long-Term Debt	$8.917M	$9.191M	$9.191M
YoY Change	-10.63%	10.38%	10.38%
Other Long-Term Liabilities	$2.207M	$2.217M	$2.217M
YoY Change	121.15%	115.88%	115.88%
Total Long-Term Liabilities	$11.12M	$11.41M	$11.41M
YoY Change	1.35%	21.96%	21.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.838M	$3.072M	$3.072M
Total Long-Term Liabilities	$11.12M	$11.41M	$11.41M
Total Liabilities	$14.96M	$14.48M	$14.48M
YoY Change	12.27%	21.8%	21.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.548M	-$6.232M
YoY Change		66.7%
Common Stock	$781.4K	$781.4K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$147.2K	$147.2K
YoY Change		-6.92%
Treasury Stock Shares		67.30K shares
Shareholders Equity	$28.16M	$30.38M	$30.38M
YoY Change
Total Liabilities & Shareholders Equity	$43.12M	$44.86M	$44.86M
YoY Change	-7.66%	0.89%	0.89%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.315M	-$1.668M	-$2.494M
YoY Change	-414.69%	-2350.1%	3085.59%
Depreciation, Depletion And Amortization	$652.1K	$604.3K	$2.468M
YoY Change	4.91%	0.51%	0.3%
Cash From Operating Activities	-$2.762M	-$1.298M	-$1.544M
YoY Change	-532.55%	-320.76%	-261.8%
INVESTING ACTIVITIES
Capital Expenditures	$682.2K	$1.490M	$3.975M
YoY Change	-184.48%	-311.49%	-252.39%
Acquisitions
YoY Change
Other Investing Activities	$20.00	$0.00	$11.00K
YoY Change	-99.82%	-100.0%	-98.91%
Cash From Investing Activities	-$682.2K	-$1.490M	-$3.964M
YoY Change	-14.36%	111.89%	148.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$748.6K	-248.2K	$1.114M
YoY Change	-58.17%	27.35%	-71.27%
NET CHANGE
Cash From Operating Activities	-$2.762M	-1.298M	-$1.544M
Cash From Investing Activities	-$682.2K	-1.490M	-$3.964M
Cash From Financing Activities	$748.6K	-248.2K	$1.114M
Net Change In Cash	-$2.696M	-3.036M	-$4.394M
YoY Change	-265.2%	878.47%	-235.8%
FREE CASH FLOW
Cash From Operating Activities	-$2.762M	-$1.298M	-$1.544M
Capital Expenditures	$682.2K	$1.490M	$3.975M
Free Cash Flow	-$3.444M	-$2.788M	-$5.519M
YoY Change	-338.18%	-315.71%	-254.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity File Number EntityFileNumber	001-12934
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	01-0382980
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	56 Evergreen Drive
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Portland
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	ME
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	04103
CY2022	dei	City Area Code CityAreaCode	(207)
CY2022	dei	Local Phone Number LocalPhoneNumber	878-2770
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.10 par value per share
CY2022	dei	Trading Symbol TradingSymbol	ICCC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	64443000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7746864	shares
CY2022	dei	Auditor Firm AuditorFirmId	344
CY2022	dei	Auditor Name AuditorName	WIPFLI LLP
CY2022	dei	Auditor Location AuditorLocation	Minneapolis, Minnesota
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5791562	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10185468	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1758600	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2694229	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6038539	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3089974	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	406055	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295197	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	13994756	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	16264868	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28441726	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26893599	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2194670	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1109133	usd
CY2022Q4	us-gaap	Goodwill Goodwill	95557	usd
CY2021Q4	us-gaap	Goodwill Goodwill	95557	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	57312	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	76416	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	76628	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26115	usd
CY2022Q4	us-gaap	Assets Assets	44860649	usd
CY2021Q4	us-gaap	Assets Assets	44465688	usd
CY2022Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	1039447	usd
CY2021Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	812207	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31764	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108012	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2000862	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1614250	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3072073	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2534469	usd
CY2022Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	9191109	usd
CY2021Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	8327122	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2217418	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1027157	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11408527	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9354279	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14480600	usd
CY2021Q4	us-gaap	Liabilities Liabilities	11888748	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7814165	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7814165	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7746864	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7741864	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	781417	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	781417	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35978364	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35692388	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6232499	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3738694	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	67301	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	72301	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	147233	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	158171	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	30380049	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	32576940	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44860649	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44465688	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18567962	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19242969	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10919183	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10587040	usd
CY2022	us-gaap	Gross Profit GrossProfit	7648779	usd
CY2021	us-gaap	Gross Profit GrossProfit	8655929	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4493872	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4168518	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3190033	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2503926	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2263817	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1726100	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9947722	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	8398544	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2298943	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	257385	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-187190	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-326512	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2486133	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69127	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7672	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9165	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2493805	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78292	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7745122	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7592290	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7745122	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7592290	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28266200	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78292	usd
CY2021	iccc	Public Offering Of Common Stock PublicOfferingOfCommonStock	17011	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4233026	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11693	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	144313	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	32576940	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2493805	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30670	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	266244	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	30380049	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2493805	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78292	usd
CY2022	us-gaap	Depreciation Depreciation	2468479	usd
CY2021	us-gaap	Depreciation Depreciation	2442036	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	19104	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	19104	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	7658	usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	7841	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	266244	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	144313	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	7334	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-30963	usd
CY2022	iccc	Non Cash Rent Expense NonCashRentExpense	-28476	usd
CY2021	iccc	Non Cash Rent Expense NonCashRentExpense	-10716	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-935629	usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	897428	usd
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-495	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2948565	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	997460	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	110858	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-26064	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	50513	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-58	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	341614	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	245760	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1543871	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	954170	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3975274	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2608649	usd
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-996000	usd
CY2022	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	11000	usd
CY2021	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	15290	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3964274	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1597359	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	4233026	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	400000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	897125	usd
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	768271	usd
CY2022	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	-19306	usd
CY2021	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	2272	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30670	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11693	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1114239	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3878720	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4393906	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3235531	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10185468	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6949937	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5791562	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10185468	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	4923	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	5110	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	338516	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	308682	usd
CY2022	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1	44998	usd
CY2021	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1	18263	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	165337	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1184727	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BUSINESS OPERATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">ImmuCell Corporation (the “Company”, “we”, “us”, “our”) was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with our initial public offering of common stock. We are an animal health company whose purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. As disclosed in Note 17, “Segment Information”, one of our business segments is dedicated to Scours and the other is focused on Mastitis. We manufacture and market the <b>First Defense<sup><b>®</b></sup></b> product line, providing <b>Immediate Immunity™</b> to prevent scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>, coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup><b>®</b></sup></b>, a treatment for lactating dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key individuals and third-party providers of critical goods and services, competition from other larger companies, the successful sale of existing products and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of the conditions, trends and concerns related to or arising from the global COVID-19 pandemic, as well as inflation, rising interest rates and potential recessionary conditions in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We are experiencing price increases and shortages in key components, supportive services, transportation and other supplies that may cause production slowdowns that affect our ability to consistently deliver our products to market.</p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P10Y
CY2020Q2	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P10Y
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5791562	usd
CY2022Q4	iccc	Bank Debt BankDebt	8897197	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	10185468	usd
CY2021Q4	iccc	Bank Debt BankDebt	9139329	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Concentration of Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">During the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">40</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">46</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">Trade accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">41</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">38</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Company C</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-weight: normal"></span></td><td style="text-align: justify"><span style="font-weight: normal">Amount is less than 10%.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
CY2022	iccc	Product Sales To Customers Percentage ProductSalesToCustomersPercentage	0.10	pure
CY2022	iccc	Trade Accounts Receivable Percentage TradeAccountsReceivablePercentage	0.10	pure
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	266244	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	144313	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	605000	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	443000	shares
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2493805	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-78292	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7745122	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7592290	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7745122	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7592290	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our inventory valuation, valuation of goodwill and long-lived assets, valuation of deferred tax assets, accrued expenses, costs of goods sold and useful lives of intangible assets.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2419982	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	971606	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3468702	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1902299	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	149855	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	216069	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6038539	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5791562	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10185468	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1758600	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2694229	usd
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1796801	usd
CY2022	us-gaap	Accounts Receivable Sale AccountsReceivableSale	46426	usd
CY2021	us-gaap	Accounts Receivable Sale AccountsReceivableSale	55490	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3089974	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	587620	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	363877	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	268713	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	42178	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	26484	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	406055	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295197	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44317346	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40886872	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15875620	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13993273	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28441726	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26893599	usd
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	127127	usd
CY2021	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	160366	usd
CY2022	us-gaap	Depreciation Depreciation	2468479	usd
CY2021	us-gaap	Depreciation Depreciation	2442036	usd
CY2022	iccc	Developed Technology Intangible Assets DevelopedTechnologyIntangibleAssets	191040	usd
CY2022	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P10Y
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19104	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19104	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57312	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	76416	usd
CY2022	iccc	Intangible Assets Description IntangibleAssetsDescription	Intangible asset amortization expense is estimated to be $19,104 per year through December 31, 2025.
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	133728	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57312	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	114624	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	76416	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	726736	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	726781	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	63261	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	18263	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	966553	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	585939	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	95550	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	82050	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	143872	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	199076	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4890	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2141	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2000862	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1614250	usd
CY2022Q1	us-gaap	Participating Mortgage Loans Unamortized Debt Discount Amount ParticipatingMortgageLoansUnamortizedDebtDiscountAmount	2000000	usd
CY2022Q1	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.0358	pure
CY2022Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0353	pure
CY2022Q4	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	19306	usd
CY2021Q4	iccc	Minimum Debt Services Coverage Ratio MinimumDebtServicesCoverageRatio	1.35	pure
CY2022Q4	iccc	Minimum Debt Services Coverage Ratio MinimumDebtServicesCoverageRatio	1	pure
CY2022	iccc	Proceeds From Issuances Of Debt ProceedsFromIssuancesOfDebt	2000000	usd
CY2022	iccc	Debt Principal Repayments DebtPrincipalRepayments	897125	usd
CY2021	iccc	Proceeds From Issuances Of Debt ProceedsFromIssuancesOfDebt	400000	usd
CY2021	iccc	Debt Principal Repayments DebtPrincipalRepayments	768271	usd
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1000000	usd
CY2022Q4	iccc	Debt Issuance Costs2022 DebtIssuanceCosts2022	7676	usd
CY2022Q4	iccc	Debt Issuance Costs2023 DebtIssuanceCosts2023	7267	usd
CY2022Q4	iccc	Debt Issuance Costs2024 DebtIssuanceCosts2024	7168	usd
CY2022Q4	iccc	Debt Issuance Costs2025 DebtIssuanceCosts2025	7168	usd
CY2022Q4	iccc	Debt Issuance Costs2026 DebtIssuanceCosts2026	5420	usd
CY2022Q4	iccc	Debt Issuance Costshereafter DebtIssuanceCostshereafter	14860	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	49559	usd
CY2022Q4	iccc	Long Term Debt2022 LongTermDebt2022	1039447	usd
CY2022Q4	iccc	Long Term Debt2023 LongTermDebt2023	1111517	usd
CY2022Q4	iccc	Long Term Debt2024 LongTermDebt2024	1155297	usd
CY2022Q4	iccc	Long Term Debt2025 LongTermDebt2025	1199843	usd
CY2022Q4	iccc	Long Term Debt2026 LongTermDebt2026	793460	usd
CY2022Q4	iccc	Long Term Debt Thereafter LongTermDebtThereafter	4930992	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	10230556	usd
CY2022Q1	iccc	Severance Agreement Description SeveranceAgreementDescription	the Company entered into an Amended and Restated Separation and Deferred Compensation Agreement (the “Deferred Compensation Agreement”) with Mr. Brigham, its President and CEO, that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham. Upon separation from the Company for any reason, Mr. Brigham’s Deferred Compensation Agreement allows Mr. Brigham to be paid, among other amounts, all earned and unused paid time off (which amount totaling $222,000 was accrued during the first quarter of 2022 and included in accounts payable and accrued expenses on the accompanying balance sheet as of December 31, 2022) and to receive up to an additional $300,000 in deferred compensation (which amount is being accrued over the three-year period ending in January 2025). This deferred compensation payment vested as to $100,000 on January 1, 2023, and will vest as to an additional $100,000 on each of January 1, 2024 and January 1, 2025, provided that Mr. Brigham is employed by the Company on these future vesting dates. The vested amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following his separation from the Company. This amount is being accrued over the three-year period ending in January 2025. As of December 31, 2022, $100,000 was included as part of accounts payable and accrued expenses on the accompanying balance sheet. In addition, upon termination of Mr. Brigham’s employment (a) by the Company other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual base salary and a lump sum payment equal to the employer portion of the costs of continued health benefits for Mr.
CY2022Q4	iccc	Capital Expenditures Committed CapitalExpendituresCommitted	294000	usd
CY2022Q4	us-gaap	Other Commitment OtherCommitment	129000	usd
CY2022Q4	iccc	Inventory Production InventoryProduction	1881000	usd
CY2022	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	134000	usd
CY2022Q4	iccc	Other Obligations OtherObligations	401000	usd
CY2019Q3	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	we entered into a lease covering approximately 14,300 square feet of office and warehouse space with a possession date of November 15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland, which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our needs in expanding our production capacity for the First Defense® product line. The original lease term was ten years with a right to renew for a second 10-year term and a right of first offer to purchase. At the time we entered into this lease, we were not reasonably assured that we would exercise this renewal option in place of other real estate options. For that reason, a 10-year period was reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. During the third quarter of 2022, we committed to lease an additional 15,400 square feet of space at 165 Industrial Way, which is connected to the original space at 175 Industrial Way, over a 20-year term. The ROU asset and lease liability for the committed space to be leased at 165 Industrial Way will be recorded upon the commencement date of the new lease, which is anticipated during the second quarter of 2023 after construction of the building shell is completed. In connection with the lease commitment for space at 165 Industrial Way, the term of the original lease for 175 Industrial Way was extended by approximately 13 years. The total lease liability over the amended term (including inflationary adjustments) aggregates $2,247,978.
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2194670	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2249182	usd
CY2022	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	149176	usd
CY2021	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	117996	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	36404	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	41400	usd
CY2022	us-gaap	Lease Cost LeaseCost	185580	usd
CY2021	us-gaap	Lease Cost LeaseCost	159396	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	148302	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	159396	usd
CY2022	iccc	Operating Lease Weighted Average Remaining Lease Term2 OperatingLeaseWeightedAverageRemainingLeaseTerm2	P20Y1M6D
CY2021	iccc	Operating Lease Weighted Average Remaining Lease Term2 OperatingLeaseWeightedAverageRemainingLeaseTerm2	P8Y1M6D
CY2022	iccc	Operating Lease Weighted Average Discount Rate Percent1 OperatingLeaseWeightedAverageDiscountRatePercent1	0.0554	pure
CY2021	iccc	Operating Lease Weighted Average Discount Rate Percent1 OperatingLeaseWeightedAverageDiscountRatePercent1	0.0477	pure
CY2022Q4	iccc	Operating Lease Future Minimum Payments Receivable In Three Years OperatingLeaseFutureMinimumPaymentsReceivableInThreeYears	155730	usd
CY2022Q4	iccc	Operating Leases Future Minimum Payment Receivable In Four Years OperatingLeasesFutureMinimumPaymentReceivableInFourYears	162384	usd
CY2022Q4	iccc	Operating Leases Future Minimum Payment Receivable In Five Years OperatingLeasesFutureMinimumPaymentReceivableInFiveYears	165090	usd
CY2022Q4	iccc	Operating Leases Future Minimum Payments Receivable In Six Years OperatingLeasesFutureMinimumPaymentsReceivableInSixYears	168395	usd
CY2022Q4	iccc	Operating Leases Future Minimum Payments Receivable In Seven Years OperatingLeasesFutureMinimumPaymentsReceivableInSevenYears	171760	usd
CY2022Q4	iccc	Operating Leases Future Minimum Payment Receivable Thereafter OperatingLeasesFutureMinimumPaymentReceivableThereafter	3049071	usd
CY2022Q4	iccc	Operating Leases Future Minimum Payment Receivable OperatingLeasesFutureMinimumPaymentReceivable	3872430	usd
CY2022Q4	iccc	Less Imputed Interest Discount Effect Of Cash Flows LessImputedInterestDiscountEffectOfCashFlows	1623248	usd
CY2022Q4	iccc	Operating Leases Future Minimum Payment Receivable Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentReceivableRemainderOfFiscalYear	2249182	usd
CY2016Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1123810	shares
CY2016Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5900000	usd
CY2016Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	5313000	usd
CY2017Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	417807	shares
CY2017Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.3
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3050000	usd
CY2017Q4	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	2734000	usd
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1636364	shares
CY2019Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.5
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000000	usd
CY2019Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	8303000	usd
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	515156	shares
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.25
CY2021Q2	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	4250000	usd
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4233000	usd
CY2017Q2	iccc	Stock Option And Incentive Plan Description StockOptionAndIncentivePlanDescription	In June 2017, our stockholders approved the 2017 Stock Option and Incentive Plan (the “2017 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan. An amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from 300,000 shares to 650,000 shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June 2022.
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.38
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.78
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.08
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.73
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.13
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.19
CY2022Q4	iccc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested	6.66
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.19
CY2022	iccc	Stock Options Covering Shares StockOptionsCoveringShares	5000	shares
CY2022Q4	us-gaap	Cash Cash	30670	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	During the year ended December 31, 2021, one director and three employees exercised stock options covering 25,000 shares by the surrender of 17,128 shares of common stock with a fair market value of $165,337 at the time of exercise and the payment of $11,693 in cash.
CY2022	iccc	Fair Value Assumptions Expected Dividend Rates FairValueAssumptionsExpectedDividendRates	0	pure
CY2022	iccc	Fair Value Assumptions Expected Volatility Rates FairValueAssumptionsExpectedVolatilityRates	0.53	pure
CY2021	iccc	Fair Value Assumptions Expected Volatility Rates FairValueAssumptionsExpectedVolatilityRates	0.54	pure
CY2022	iccc	Fair Value Assumptions Expected Terms FairValueAssumptionsExpectedTerms	P5Y10M24D
CY2021	iccc	Fair Value Assumptions Expected Terms FairValueAssumptionsExpectedTerms	P5Y
CY1995Q3	us-gaap	Employee Stock Ownership Plan Esop Weighted Average Purchase Price Of Shares Purchased EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased	70
CY2022	iccc	Exercisable And Transferable Description ExercisableAndTransferableDescription	The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).
CY2022	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	Upon the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company’s common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company’s assets or earning power were sold, each Right would entitle its holder to purchase, at the Rights’ then-current purchase price, a number of shares of the acquiring company’s common stock having a market value at that time equal to twice the Right’s exercise price.
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	At any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment.
CY2021Q3	iccc	Acquiring Person Percentage AcquiringPersonPercentage	0.20	pure
CY2015Q2	iccc	Acquiring Person Percentage AcquiringPersonPercentage	0.20	pure
CY2022	us-gaap	Employee Stock Ownership Plan Esop Plan Description EmployeeStockOwnershipPlanESOPPlanDescription	Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders held in June 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Recognizing that there might be a substantial number of broker non-votes, our Board of Directors, which has the authority to amend the Rights Plan, disclosed that it would be guided by the votes actually cast on this proposal in deciding whether to extend the expiration date of such plan by one year. Of the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2023.
CY2022	iccc	Total Product Sales TotalProductSales	18567962	usd
CY2022	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2021	iccc	Total Product Sales TotalProductSales	19242969	usd
CY2021	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18567962	usd
CY2022	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19242969	usd
CY2021	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	7334	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-30963	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	153100	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	18810	usd
CY2022	us-gaap	Other Income OtherIncome	912	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	187190	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	326512	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7658	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7841	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7672	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9165	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.13	pure
CY2022	us-gaap	Tax Credit Carryforward Description TaxCreditCarryforwardDescription	As of December 31, 2022, we had federal net operating loss carryforwards of $15,516,167 of which $13,804,260 do not expire and of which $1,711,907 expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards of $1,106,340 that expire in 2037 through 2038 (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of $673,233 that expire in 2027 through 2042 (if not utilized before then) and state tax credit carryforwards of $791,397 that expire in 2023 through 2042 (if not utilized before then).
	iccc	Noncash Income Tax Expense NoncashIncomeTaxExpense	563252	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7672	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9165	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7672	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9165	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-576780	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-63097	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-88533	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-14990	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	665313	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	78087	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	665313	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78087	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7672	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9165	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-522088	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14517	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-47643	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0192	pure
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7522	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1088	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	36652	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0148	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	13716	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.1984	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	131361	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0528	pure
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	79901	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-1.1558	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	665313	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2676	pure
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	78087	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1.1296	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	6799	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0027	pure
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	4258	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0616	pure
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	7672	usd
CY2022	iccc	Income Tax Expensebenefitrate IncomeTaxExpensebenefitrate	0.0031	pure
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	9165	usd
CY2021	iccc	Income Tax Expensebenefitrate IncomeTaxExpensebenefitrate	0.1326	pure
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2530472	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2483145	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	673233	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	557795	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3258395	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3094283	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	817617	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	809618	usd
CY2022	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	341683	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	23370	usd
CY2022Q4	iccc	Deferred Tax Assets Tax Deferred Expense Other1 DeferredTaxAssetsTaxDeferredExpenseOther1	15587	usd
CY2021Q4	iccc	Deferred Tax Assets Tax Deferred Expense Other1 DeferredTaxAssetsTaxDeferredExpenseOther1	-6289	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	32787	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14178	usd
CY2022Q4	iccc	Incentive Compensation IncentiveCompensation	76554	usd
CY2021Q4	iccc	Incentive Compensation IncentiveCompensation	57001	usd
CY2022Q4	iccc	Deferred Tax Asset Valuation Allowance DeferredTaxAssetValuationAllowance	-2708754	usd
CY2021Q4	iccc	Deferred Tax Asset Valuation Allowance DeferredTaxAssetValuationAllowance	-2043441	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	18567962	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10919183	usd
CY2022	us-gaap	Gross Profit GrossProfit	7648779	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4493872	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3190033	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2263817	usd
CY2022	iccc	Operating Activities OperatingActivities	9947722	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2298943	usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	19242969	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10587040	usd
CY2021	us-gaap	Gross Profit GrossProfit	8655929	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4168518	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2503926	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1726100	usd
CY2021	iccc	Operating Activities OperatingActivities	8398544	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	257385	usd
CY2022Q4	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	44860649	usd
CY2021Q4	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	44465688	usd
CY2022	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2495241	usd
CY2021	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2468981	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3975274	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2608649	usd
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	587677	usd
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	651424	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	46426	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	55490	usd
CY2022	iccc	Employee Benefits Description EmployeeBenefitsDescription	We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate.
CY2022	us-gaap	Defined Benefit Plans General Information DefinedBenefitPlansGeneralInformation	We currently match 100% of the first 3% of each employee’s salary that is contributed to the Plan and 50% of the next 2% of each employee’s salary that is contributed to the Plan.
CY2022	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	159058	usd
CY2021	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	139401	usd
CY2022	us-gaap	Subsequent Event Description SubsequentEventDescription	We anticipate this slowdown will reduce sales during the first quarter of 2023 to between approximately $3,200,000 and $3,400,000. Due to the resulting loss in gross margin caused by the reduced sales level, we have decided to defer, for the time being, certain capital expenditures. The related one-time charge to costs of goods sold during the first quarter of 2023 is expected to be up to approximately $200,000, of which approximately $114,000 worth of product remains under evaluation. During the first quarter of 2023, the Debt Service Coverage (DSC) ratio covenant for the year ending December 31, 2023 was waived by our bank. Instead, we are required to meet a minimum DSC ratio requirement of 1.35 for the twelve-month periods ending June 30, 2024, September 30, 2024 and December 31, 2024 and then again annually after that.
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	iccc	Excess Tax Benefit From Shares Based Compensation Financing Activities ExcessTaxBenefitFromSharesBasedCompensationFinancingActivities		usd
CY2021	us-gaap	Other Income OtherIncome		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid		usd
CY2021Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent		usd
CY2022Q4	iccc	Deferred Tax Asset Net DeferredTaxAssetNet		usd
CY2021Q4	iccc	Deferred Tax Asset Net DeferredTaxAssetNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000811641

Files In Submission

Name	View Source	Status
f10k2022_immucellcorp_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-024080-index-headers.html	Edgar Link	pending
0001213900-23-024080-index.html	Edgar Link	pending
0001213900-23-024080.txt	Edgar Link	pending
0001213900-23-024080-xbrl.zip	Edgar Link	pending
ex10-23_001.jpg	Edgar Link	pending
f10k2022ex10-10_immucellcorp.htm	Edgar Link	pending
f10k2022ex10-13_immucellcorp.htm	Edgar Link	pending
f10k2022ex10-15_immucellcorp.htm	Edgar Link	pending
f10k2022ex10-23_immucellcorp.htm	Edgar Link	pending
f10k2022ex10-7_immucellcorp.htm	Edgar Link	pending
f10k2022ex23-1_immucellcorp.htm	Edgar Link	pending
f10k2022ex31_immucellcorp.htm	Edgar Link	pending
f10k2022ex32_immucellcorp.htm	Edgar Link	pending
f10k2022_immucellcorp.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
iccc-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
iccc-20221231_cal.xml	Edgar Link	unprocessable
iccc-20221231_def.xml	Edgar Link	unprocessable
iccc-20221231_lab.xml	Edgar Link	unprocessable
iccc-20221231_pre.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCC
IMMUCELL CORP /DE/ Stock $iccc

2023 Q1 Form 10-K Financial Statement

#000121390023024080 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC IMMUCELL CORP /DE/ Stock $iccc

2023 Q1 Form 10-K Financial Statement

#000121390023024080 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC
IMMUCELL CORP /DE/ Stock $iccc